26561559Shah JJ, Jakubowiak AJ, O'Connor OA, Orlowski RZ, Harvey RD, Smith MR, Lebovic D, Diefenbach C, Kelly K, Hua Z, Berger AJ, Mulligan G, Faessel HM, Tirrell S, Dezube BJ, Lonial SClinical cancer research : an official journal of the American Association for Cancer ResearchAntineoplastic Agents; Cyclopentanes; Lymphoma; Molecular Targeted Therapy; Multiple Myeloma; Pyrimidines; UbiquitinsAdult; Aged; Aged, 80 and over; Biomarkers; Drug Administration Schedule; Drug Monitoring; Drug Resistance, Neoplasm; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; NEDD8 Protein; Neoplasm Recurrence, Local; Retreatment; Treatment OutcomePhase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma. Clin Cancer Res. 2016 Jan 01; 22(1):34-43.Clin Cancer Res2015-11-11T00:00:002015Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma.prns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000369Living Beings93664810.461294Aged, 80 and overD000368Living Beings1341183530.294764AgedD000328Living Beings1578255770.254432AdultD000970Chemicals & Drugs40723510.435461Antineoplastic AgentsD003517Chemicals & Drugs15270.98412CyclopentanesD008875Concepts & IdeasLiving Beings1473249570.258811Middle AgedD005260Physiology1992444050.191167FemaleD006801Living Beings2262862810.130052HumansD015415Concepts & Ideas59717090.619575BiomarkersD008297Physiology1931408600.201617MaleD019008Physiology1805890.751116Drug Resistance, NeoplasmMedicine-Hematology and OncologyD008223Disorders1142620.859106LymphomaD009101Disorders823070.737421Multiple MyelomaD016896Concepts & Ideas101179490.402389Treatment OutcomeD009364Disorders33613050.61985Neoplasm Recurrence, LocalD019233Procedures701070.968755RetreatmentD011743Chemicals & Drugs1373700.795259PyrimidinesD058990Procedures1352660.831095Molecular Targeted TherapyD016903Procedures751180.922751Drug MonitoringD014452Chemicals & Drugs25380.983385UbiquitinsD000075687110.999825NEDD8 ProteinD004334Concepts & Ideas2609160.852414Drug Administration ScheduleD020714Concepts & Ideas902700.919873Maximum Tolerated DoseUniversity of ChicagoAndrzejJakubowiak1mhjCqp1G+POmHtvQFPt+2z5/syyp7BaZQ==Andrzej Jakubowiak41.78927490000000-87.601250000000002384Jakubowiak, AndrzejProfessortrue1ProfessorProfessorAuthorship 8535520.1398760.1398761authors10.2523has subject area